8.50 -0.01 (-0.12%)
After hours: 4:00PM EDT
|Bid||7.50 x 3000|
|Ask||8.57 x 2900|
|Day's Range||7.31 - 8.95|
|52 Week Range||7.31 - 24.56|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
If you want to know who really controls Unity Biotechnology Inc (NASDAQ:UBX), then you’ll have to look at the makeup of its share registry. Institutions often own shares in moreRead More...
"The evidence is mounting, both in our company and outside, that you can intervene and you can change the course of these specific diseases," says Unity Biotechnology CEO Keith Leonard.
Unity Biotechnology is a company designing drugs and treatments that can make a person functional and free of the diseases associated with aging for as long as possible. The company — backed by Jeff Bezos and Peter Thiel —went public in May and is listed on NASDAQ. Of the many people currently involved in searching for ways to slow down or delay the effects of growing older, Nathaniel David might actually have a shot.